placebo + clomiphene citrate

placebo + clomiphene citrate refers to a specific treatment arm or intervention regimen used in clinical trials, most notably in a Phase 2 double-blind, double-dummy study (NCT00116155) sponsored by Ferring Pharmaceuticals. In this study design, patients in the active reference arm received oral clomiphene citrate alongside a placebo version of an experimental transdermal iontophoretic patch (Lutrepatch). Clomiphene citrate is a selective estrogen receptor modulator (SERM) that primarily acts as a competitive antagonist at estrogen receptors in the hypothalamus. By blocking the negative feedback of endogenous estrogens, it stimulates an increase in the pulsatile secretion of gonadotropin-releasing hormone (GnRH), which subsequently elevates the levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. This hormonal surge promotes ovarian follicle maturation and induces ovulation in women with anovulatory or oligoovulatory infertility. The placebo component of this regimen is an inactive delivery system designed to maintain the study's blinding while comparing the efficacy of pulsatile GnRH delivery against the standard oral treatment.